Table 2.
Main aspects related to COVID-19 disease.
| N = 63 patients | |
|---|---|
| COVID19 diagnosis | |
| Laboratory confirmed | 49.2% |
| PCR-SARS-CoV-2 | 38.1% |
| IgG-SARS-CoV-2 | 12.7% |
| IgM-SARS-CoV-2 | 6.3% |
| Suspected | 50.8% |
| Duration of symptoms (days)/median (IQR) | 6 (2–9.25) |
| Fever | 66.1% |
| Cough | 66.1% |
| Dyspnoea | 46.8% |
| Anosmia | 11.3% |
| Ageusia | 9.7% |
| Diarrhea | 22.6% |
| Headache | 14.5% |
| Weakness | 25.8% |
| Myalgia/arthralgia | 24.2% |
| Chest X-ray | 92.1% |
| Pneumonia | 47.5% |
| Unilateral | 32.1% |
| Bilateral | 67.9% |
| WHO Covid-19 severity score | 28.6% |
| CURB-65 score > 2 | 7.9% |
| Lymphopenia (< 1000/μL) | 26.5% |
| Ferritine > 1000 mcg/L | 25% |
| D-dimer > 2500 ng/mL | 4.8% |
| Hospital admission | 32.3% |
| Oxygen support requirements | 30.2% |
| FiO2 ≥ 0.5 | 6.7% |
| Chloroquine or Hydroxycloroquine | 49.2% |
| LMWH | 46% |
| Corticosteroids | 19% |
| Cyclosporine | 12.7% |
| Tocilizumab | 6.3% |